This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Recro Pharma, Inc.
Drug Names(s): Fadolmidine
Description: Fadolmidine is a full agonist of all subtypes of alpha-2 adrenoreceptors. Fadolmidine does not cross the blood brain barrier and this accounts for the targeting of Fadolmidine use for either IT administration for pain or anesthesia, or potentially for topical use to treat pain associated with regional nerve pain from underlying nerve damage, also called “neuropathies”.
Orion and Recro
In July 2010, Recro Pharma announced that they have entered into a License Agreement with Orion for Fado. Under the Fadolmidine License Agreement, Recro was granted an exclusive license under Orion Know-How and Orion Patent Rights to commercialize products in the territory, as defined in such agreement, and to use, research, develop, and have made products worldwide solely for purposes of commercialization. Recro will pay milestone payments to Orion of up to 12.2 million Euros ($16.1 million as of December 31, 2012) based on regulatory filings and approval and on commercialized net sales levels. There are also royalty payments to be paid at varying percentages based on net sale levels.
Partners: Orion Corporation
Additional information available to subscribers only: